Ayyan Investment Past Earnings Performance
Past criteria checks 0/6
Ayyan Investment's earnings have been declining at an average annual rate of -81.6%, while the Healthcare industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 5.9% per year.
Key information
-81.6%
Earnings growth rate
-80.9%
EPS growth rate
| Healthcare Industry Growth | 12.3% |
| Revenue growth rate | 5.9% |
| Return on equity | -50.2% |
| Net Margin | -61.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
More Unpleasant Surprises Could Be In Store For Ayyan Investment Company's (TADAWUL:2140) Shares After Tumbling 29%
Apr 01
Ayyan Investment Company's (TADAWUL:2140) Business Is Trailing The Industry But Its Shares Aren't
Jan 19Can Ayyan Investment (TADAWUL:2140) Continue To Grow Its Returns On Capital?
Mar 15The Ayyan Investment (TADAWUL:2140) Share Price Has Gained 68% And Shareholders Are Hoping For More
Jan 30With EPS Growth And More, Ayyan Investment (TADAWUL:2140) Is Interesting
Jan 04We're Not Counting On Ayyan Investment (TADAWUL:2140) To Sustain Its Statutory Profitability
Dec 08
Revenue & Expenses Breakdown
How Ayyan Investment makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 364 | -225 | 123 | 0 |
| 31 Dec 23 | 333 | -216 | 121 | 0 |
| 30 Sep 23 | 296 | -174 | 91 | 0 |
| 30 Jun 23 | 270 | -134 | 98 | 0 |
| 31 Mar 23 | 260 | -105 | 85 | 0 |
| 31 Dec 22 | 266 | -45 | 74 | 0 |
| 30 Sep 22 | 270 | -22 | 91 | 0 |
| 30 Jun 22 | 268 | -2 | 71 | 0 |
| 31 Mar 22 | 273 | 10 | 73 | 0 |
| 31 Dec 21 | 270 | 4 | 75 | 0 |
| 30 Sep 21 | 273 | 10 | 75 | 0 |
| 30 Jun 21 | 274 | 12 | 77 | 0 |
| 31 Mar 21 | 265 | 16 | 70 | 0 |
| 31 Dec 20 | 255 | 24 | 66 | 0 |
| 30 Sep 20 | 260 | 19 | 78 | 0 |
| 30 Jun 20 | 254 | 15 | 76 | 0 |
| 31 Mar 20 | 251 | 13 | 76 | 0 |
| 31 Dec 19 | 246 | -1 | 74 | 0 |
| 30 Sep 19 | 238 | 14 | 61 | 0 |
| 30 Jun 19 | 235 | 13 | 61 | 0 |
| 31 Mar 19 | 230 | 11 | 58 | 0 |
| 31 Dec 18 | 226 | 7 | 59 | 0 |
| 30 Sep 18 | 217 | -11 | 60 | 0 |
| 30 Jun 18 | 210 | -15 | 59 | 0 |
| 31 Mar 18 | 211 | -13 | 60 | 0 |
| 31 Dec 17 | 209 | -9 | 60 | 0 |
| 30 Sep 17 | 203 | -14 | 57 | 0 |
| 30 Jun 17 | 199 | -15 | 57 | 0 |
| 31 Mar 17 | 193 | -28 | 56 | 0 |
| 31 Dec 16 | 192 | -32 | 56 | 0 |
| 30 Sep 16 | 195 | -18 | 55 | 0 |
| 30 Jun 16 | 193 | -3 | 53 | 0 |
| 31 Mar 16 | 191 | 45 | 53 | 0 |
| 31 Dec 15 | 151 | 52 | 43 | 0 |
| 30 Sep 15 | 103 | 26 | 36 | 0 |
| 30 Jun 15 | 61 | 34 | 26 | 0 |
| 31 Mar 15 | 16 | -5 | 14 | 0 |
| 31 Dec 14 | 7 | -4 | 13 | 0 |
| 30 Sep 14 | 8 | 33 | 6 | 0 |
| 30 Jun 14 | 12 | 15 | 6 | 0 |
| 31 Mar 14 | 17 | 21 | 7 | 0 |
| 31 Dec 13 | 21 | 16 | 7 | 0 |
| 30 Sep 13 | 18 | 2 | 6 | 0 |
| 30 Jun 13 | 14 | -1 | 5 | 0 |
Quality Earnings: 2140 is currently unprofitable.
Growing Profit Margin: 2140 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2140 is unprofitable, and losses have increased over the past 5 years at a rate of 81.6% per year.
Accelerating Growth: Unable to compare 2140's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2140 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (27.4%).
Return on Equity
High ROE: 2140 has a negative Return on Equity (-50.21%), as it is currently unprofitable.